According to the latest report by IMARC Group, titled "Cardiac Prosthetic Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028," the global cardiac prosthetic devices market reached a value of US$ 6.2 Billion in 2022. Cardiac prosthetic devices are artificial devices that are utilized to replace or support the function of the damaged heart tissues. They operate by mimicking the functioning of a healthy heart and prevents blockages in the heart valves. These devices are increasingly being used to improve the survival rates of patients with cardiovascular diseases (CVDs) and enhance their quality of life. Some of the most commonly used cardiac prosthetic devices include pacemakers, annuloplasty rings and ventricular assist devices.
Global Cardiac Prosthetic Devices Market Trends:
The global market is primarily driven by the rising prevalence of CVDs among the masses. This can be attributed to sedentary lifestyles led by the masses and the increasing incidences of hypertension among individuals. Cardiovascular conditions like stroke, cardiomyopathy and Coronary Artery Disease (CAD) often lead to high mortality rates. This has impelled healthcare professionals to opt for efficient cardiac prosthetic devices for their treatment across the globe. Additionally, the rising geriatric population that is susceptible to develop such medical conditions is providing an impetus to the market growth. The market is further driven by the continual technological advancements in the market that have led to the advent of innovative prosthetic solutions. For instance, modern implantable cardioverter defibrillators are gaining widespread prominence across the healthcare sector as they can be implanted into a patient’s body to perform cardioversion, defibrillation and pacing through a single device. The batteries of these devices are also equipped with modern technology to last more than a decade, thereby improving the longevity of the prosthetics. Numerous players have also launched suture-less valve replacements that are manufactured using durable and biocompatible raw materials, which is expected to gain popularity in the upcoming years. Some of the other factors contributing to the market growth include the growing preference for prosthetic devices that can be implanted through minimally invasive (MI) procedures and the continual developments in the healthcare infrastructure. On account of the aforementioned factors, the market is expected to reach a value of US$ 10.0 Billion by 2028, expanding at a CAGR of 8.1% during 2023-2028.
- On the basis of the product type, the market has been divided into valves (mechanical, tissue, stented tissue, stentless tissue and transcatheter valves), pacemakers, implantable pacemakers (single-, dual- and triple-chamber battery pacemakers), external pacemakers, and others.
- Based on the end-user, the market has been classified into hospitals, clinics and cardiac centers, ambulatory surgical centers, and others.
- On the geographical front, the market has been segregated into North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Latin America (Brazil, Mexico and others), and Middle East and Africa.
- The competitive landscape of the market has been studied in the report with the detailed profiles of the key players. Some of these players include Abbott Laboratories, Biotronik, Boston Scientific Corporation, Edwards Lifesciences Corporation, Lepu Medical Technology Co. Ltd., Medtronic Inc., Meril Life Sciences Pvt. Ltd., Siemens Healthcare GmbH, Sorin Group, and St. Jude Medical Inc.
|Base Year of the Analysis
||Product Type, End-User, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Abbott Laboratories, Biotronik, Boston Scientific Corporation, Edwards Lifesciences Corporation, Lepu Medical Technology Co. Ltd., Medtronic Inc., Meril Life Sciences Pvt. Ltd., Siemens Healthcare GmbH, Sorin Group and St. Jude Medical Inc.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800